Miami, FL – May 20, 2023 – Cahero Investments, a prominent investment firm headquartered in Miami, Florida, is delighted to announce the launch of its diverse portfolio of medium- and long-term investment opportunities designed to cater to its clients’ specific needs and preferences. With a focus on private market investments, Cahero Investments offers a wide range of investment options managed by industry specialists and experienced advisors.
In addition to its investment offerings, Cahero Investments provides comprehensive financial planning services, including asset and cash management, risk management, financial planning, and lifestyle management. The company’s unique approach prioritizes guaranteed investments, safeguarding against inflation and depreciation to ensure the preservation of clients’ funds’ purchasing power over time.
Cahero Investments employs a venture capital strategy, investing in rapidly growing biotechnology companies engaged in innovative pharmaceutical research, development, and marketing. The firm focuses on biotech companies addressing significant unmet medical needs, which have the potential for above-average increases in sales and profits. Cahero Investments expands its holdings in promising small and mid-cap companies and investments in successful large-cap companies, primarily in the biotech sector.
Key highlights of Cahero Investments’ investment technique:
- Expert portfolio management: The portfolio comprises a maximum of 35 positions, with a primary focus on small and mid-cap biotech companies.
- Leadership and expertise: The team consists of investment management experts with extensive experience and serves on an esteemed board of directors.
- Thorough due diligence: A multi-step procedure is followed, including fundamental analysis and sustainability criteria evaluation.
- Diversified portfolio: Cahero Investments focuses on mid- and small-cap biotech companies, targeting established areas like oncology, orphan diseases, and neurological indications, as well as emerging technologies such as RNA-based platforms, cell and gene therapies, and more.
- Asset classes and risk management: Cahero Investments primarily invests in publicly traded stocks, maintaining at least 90% of holdings in publicly traded companies and over 50% of total assets in equity investments. Corporate bonds are considered during declining stock market conditions, and options are used as a hedge against currency exposure.
Cahero Investments conducts an exhaustive, multistage due diligence process, thoroughly examining a company’s financial statements, competitive environment, R&D pipeline, patent portfolio, and customer feedback before making investment decisions. The company emphasizes close contact with company executives and relies on the knowledge and analysis of its distinguished Board of Directors and experienced Investment Management Team of Bellevue Asset Management AG. Additionally, Cahero Investments benefits from a vast international network of physicians and specialists in specific subsectors of the biotechnology industry for guidance and support.
Cahero Lab LLC, a subsidiary of Cahero Investments, specializes in investing in pharmaceutical firms that own patents, with a focus on companies that demonstrate profitability and have triple A clients. The investment collateral is the patent rights, and income is generated through patent licensing and royalty fees. Cahero Lab offers a competitive annual yield of 12% and charges an origination fee of 3% and a property ownership fee of 20% of ownership under the patent collateralization. The minimum investment term is 5 years, with a minimum investment ticket of $300,000 USD.
For more information about Cahero Investments and its diverse investment opportunities, please visit https://www.caheroinvestments.com/.
*Contact:*
Alfonso Cahero
Cahero Investments: at Cahero.com
Phone: +1 (305) 749-5474
